Claims for Patent: 12,599,611

Summary for Patent: 12,599,611

Title:	Methods and compositions for treating seizure disorders in pediatric patients
Abstract:	Compositions for intranasal delivery of benzodiazepines, such as diazepam, midazolam, and lorazepam and methods for their use to treat and prevent seizures in pediatric subjects aged 2-5, inclusive. Compositions for rapid therapeutic onset with a decreased incidence and/or severity of adverse effects after administration and methods of improving patient compliance with a prescribed treatment regimen.
Inventor(s):	Adrian L. Rabinowicz, Enrique J. Carrazana
Assignee:	Neurelis Inc
Application Number:	US17/837,198
Patent Claims:	1. A method of treating intermittent, stereotypic episodes of frequent seizure activity that are distinct from a subject's usual seizure pattern in a pediatric subject that is 2 to 5 years old and 23 to 33 kg in body weight having epilepsy, said method comprising: intranasally administering a pharmaceutical solution to the pediatric subject, wherein the pharmaceutical solution is one spray in each nostril of 100 μL of pharmaceutical solution having a diazepam concentration of 75 mg/mL, 0.25% w/v dodecyl maltoside, and a carrier system comprising 10.5% w/v benzyl alcohol; wherein said administering is to a nasal mucosal membrane of the pediatric subject to treat the intermittent, stereotypic episodes of frequent seizure activity that are distinct from the subject's usual seizure pattern in the pediatric subject. 2. The method of claim 1, wherein the carrier system further comprises 56.5% w/V vitamin E and an amount of ethanol sufficient to reach a volume of 100 μL. 3. The method of claim 1, wherein the pharmaceutical solution is provided in a pre-primed single use dosage device. 4. The method of claim 1, wherein said administering reduces clinical seizure activity in the pediatric subject for a period of at least 48 hours after said administering. 5. The method of claim 1, wherein said administering prevents a second seizure in the pediatric subject for a period of at least 8 hours after said administering. 6. The method of claim 1, wherein said administering prevents a second seizure in the pediatric subject for a period of at least 48 hours after said administering. 7. The method of claim 1, wherein the pediatric subject does not require a second administration of said composition within at least 24-hours of experiencing a first seizure. 8. The method of claim 1, wherein the administering is performed in a prodromal phase or pre-ictal phase of a seizure. 9. The method of claim 1, wherein the administering is performed in an ictal phase of a seizure. 10. The method of claim 1, wherein said administering achieves 96% to 97% bioavailability of an equivalent dose of intravenously administered diazepam. 11. The method of claim 1, wherein the pharmaceutical solution is self-administered by the subject. 12. A method of treating intermittent, stereotypic episodes of frequent seizure activity that are distinct from a subject's usual seizure pattern in a pediatric subject that is 2 to 5 years old and 6 to 11 kg in body weight having epilepsy, said method comprising: intranasally administering a pharmaceutical solution to the pediatric subject, wherein the pharmaceutical solution is one spray in a single nostril of 100 μL of the pharmaceutical solution having a diazepam concentration of 50 mg/mL, 0.25% w/v dodecyl maltoside and a carrier system comprising 10.5% w/v benzyl alcohol; wherein said administering is to a nasal mucosal membrane of the pediatric subject to treat the intermittent, stereotypic episodes of frequent seizure activity that are distinct from the subject's usual seizure pattern in the pediatric subject. 13. The method of claim 12, wherein the carrier system further comprises 56.5% w/V vitamin E and an amount of ethanol sufficient to reach a volume of 100 μL. 14. The method of claim 12, wherein the pharmaceutical solution is provided in a pre-primed single use dosage device. 15. The method of claim 12, wherein said administering reduces clinical seizure activity in the pediatric subject for a period of at least 48 hours after said administering. 16. The method of claim 12, wherein said administering prevents a second seizure in the pediatric subject for a period of at least 8 hours after said administering. 17. The method of claim 12, wherein said administering prevents a second seizure in the pediatric subject for a period of at least 48 hours after said administering. 18. The method of claim 12, wherein the pediatric subject does not require a second administration of said composition within at least 24-hours of experiencing a first seizure. 19. The method of claim 12, wherein the administering is performed in a prodromal phase or pre-ictal phase of a seizure. 20. The method of claim 12, wherein the administering is performed in an ictal phase of a seizure. 21. The method of claim 12, wherein said administering achieves 96% to 97% bioavailability of an equivalent dose of intravenously administered diazepam. 22. The method of claim 12, wherein the pharmaceutical solution is self-administered by the subject. 23. A method of treating intermittent, stereotypic episodes of frequent seizure activity that are distinct from a subject's usual seizure pattern in a pediatric subject that is 2 to 5 years old and 12 to 22 kg in body weight having epilepsy, said method comprising: intranasally administering a pharmaceutical solution to the pediatric subject, wherein the pharmaceutical solution one spray in a single nostril of 100 μL of the pharmaceutical solution having a diazepam concentration of 100 mg/mL, 0.25% w/v dodecyl maltoside and a carrier system comprising 10.5% w/v benzyl alcohol; and wherein said administering is to a nasal mucosal membrane of the pediatric subject to treat the intermittent, stereotypic episodes of frequent seizure activity that are distinct from the subject's usual seizure pattern in the pediatric subject. 24. The method of claim 23, wherein the carrier system further comprises 56.5% w/V vitamin E and an amount of ethanol sufficient to reach a volume of 100 μL. 25. The method of claim 23, wherein the pharmaceutical solution is provided in a pre-primed single use dosage device. 26. The method of claim 23, wherein said administering reduces clinical seizure activity in the pediatric subject for a period of at least 48 hours after said administering. 27. The method of claim 23, wherein said administering prevents a second seizure in the pediatric subject for a period of at least 8 hours after said administering. 28. The method of claim 23, wherein said administering prevents a second seizure in the pediatric subject for a period of at least 48 hours after said administering. 29. The method of claim 23, wherein the pediatric subject does not require a second administration of said composition within at least 24-hours of experiencing a first seizure. 30. The method of claim 23, wherein the administering is performed in a prodromal phase or pre-ictal phase of a seizure. 31. The method of claim 23, wherein the administering is performed in an ictal phase of a seizure. 32. The method of claim 23, wherein said administering achieves 96% to 97% bioavailability of an equivalent dose of intravenously administered diazepam. 33. The method of claim 23, wherein the pharmaceutical solution is self-administered by the subject.